SI21078A - Metode za zdravljenje revmatičnih bolezni z uporabo topne molekule CTLA4 - Google Patents

Metode za zdravljenje revmatičnih bolezni z uporabo topne molekule CTLA4 Download PDF

Info

Publication number
SI21078A
SI21078A SI200120046A SI200120046A SI21078A SI 21078 A SI21078 A SI 21078A SI 200120046 A SI200120046 A SI 200120046A SI 200120046 A SI200120046 A SI 200120046A SI 21078 A SI21078 A SI 21078A
Authority
SI
Slovenia
Prior art keywords
ctla4
soluble
molecule
molecules
val
Prior art date
Application number
SI200120046A
Other languages
English (en)
Slovenian (sl)
Inventor
Robert Cohen
Suzette Carr
David Hagerty
Robert J. Peach
Jean-Claude Becker
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22804919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI21078(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI21078A publication Critical patent/SI21078A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
SI200120046A 2000-07-03 2001-07-02 Metode za zdravljenje revmatičnih bolezni z uporabo topne molekule CTLA4 SI21078A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21591300P 2000-07-03 2000-07-03
PCT/US2001/021204 WO2002002638A2 (en) 2000-07-03 2001-07-02 Methods for treating rheumatic diseases using a soluble ctla4 molecule

Publications (1)

Publication Number Publication Date
SI21078A true SI21078A (sl) 2003-06-30

Family

ID=22804919

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200131067T SI1935427T1 (en) 2000-07-03 2001-07-02 USE OF HEATED CTLA4 MUTANT MOLECULES
SI200130864T SI1372696T1 (sl) 2000-07-03 2001-07-02 Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4
SI200120046A SI21078A (sl) 2000-07-03 2001-07-02 Metode za zdravljenje revmatičnih bolezni z uporabo topne molekule CTLA4

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200131067T SI1935427T1 (en) 2000-07-03 2001-07-02 USE OF HEATED CTLA4 MUTANT MOLECULES
SI200130864T SI1372696T1 (sl) 2000-07-03 2001-07-02 Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4

Country Status (39)

Country Link
US (1) US7455835B2 (bg)
EP (4) EP3384924A1 (bg)
JP (1) JP2004517806A (bg)
KR (3) KR100864120B1 (bg)
CN (1) CN1318086C (bg)
AR (2) AR035037A1 (bg)
AT (1) ATE401909T1 (bg)
AU (2) AU7317401A (bg)
BG (2) BG66024B1 (bg)
BR (1) BR0112104A (bg)
CA (2) CA2413190C (bg)
CY (3) CY1109786T1 (bg)
CZ (1) CZ303959B6 (bg)
DE (1) DE60135029D1 (bg)
DK (2) DK1935427T3 (bg)
EE (1) EE05378B1 (bg)
ES (2) ES2310557T3 (bg)
HK (1) HK1058486A1 (bg)
HR (1) HRP20030071B1 (bg)
HU (3) HU226847B1 (bg)
IL (2) IL153593A0 (bg)
IS (1) IS2834B (bg)
LT (2) LT1935427T (bg)
LV (1) LV12993B (bg)
MX (1) MXPA02012603A (bg)
MY (1) MY137552A (bg)
NO (3) NO20026264L (bg)
PE (1) PE20020772A1 (bg)
PL (2) PL212205B1 (bg)
PT (2) PT1372696E (bg)
RS (1) RS50811B (bg)
RU (1) RU2287340C2 (bg)
SI (3) SI1935427T1 (bg)
SK (1) SK287940B6 (bg)
TR (1) TR201807700T4 (bg)
TW (2) TWI311564B (bg)
UY (1) UY26815A1 (bg)
WO (1) WO2002002638A2 (bg)
ZA (1) ZA200210058B (bg)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
EE05458B1 (et) * 2000-05-26 2011-08-15 Bristol-Myers Squibb Company CTL4 lahustuvad mutantsed molekulid ja nende kasutamine
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AU2001275411B2 (en) * 2000-06-09 2005-04-28 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
BR0112104A (pt) * 2000-07-03 2004-07-20 Bristol Myers Squibb Co Processos para tratamento de doenças reumáticas usando uma molécula de ctla4 solúvel
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
JP2004535364A (ja) * 2001-01-26 2004-11-25 エモリー・ユニバーシティ 臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
EP1496931A4 (en) * 2002-04-19 2009-07-01 Bristol Myers Squibb Co METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
MXPA05006523A (es) * 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
BRPI0413326A (pt) * 2003-08-04 2006-10-10 Bristol Myers Squibb Co métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
US7815765B2 (en) * 2004-04-01 2010-10-19 Swei Mu Wang Method for forming laminated synthetic leather
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
CN101584858A (zh) * 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
ES2439641T3 (es) 2005-12-20 2014-01-24 Bristol-Myers Squibb Company Composiciones y procedimientos de producción de una composición
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
DK2222697T3 (da) * 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunsuppressive polypeptider og nukleinsyrer
AU2014250683B2 (en) * 2007-11-01 2015-11-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
AU2012202324B2 (en) * 2007-11-01 2014-08-28 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
ES2615861T3 (es) * 2008-10-30 2017-06-08 Yeda Research And Development Company Ltd. Células T de memoria central anti-terceros, métodos de producción de las mismas y uso de las mismas en trasplante y tratamiento de enfermedades
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN102030828B (zh) * 2009-09-25 2014-10-29 上海抗体药物国家工程研究中心有限公司 一种高亲和力的CTLA4-Ig融合蛋白突变体
JP5705242B2 (ja) * 2010-02-19 2015-04-22 ゼンコア インコーポレイテッド 新規ｃｔｌａ４−ｉｇ免疫アドヘシン
TW201134481A (en) 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
WO2011146395A2 (en) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
KR20130105652A (ko) 2010-09-08 2013-09-25 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 안정하고 장기간의 인그래프트먼트를 위한 면역억제 약물의 조합
BR112013005756A2 (pt) 2010-09-08 2018-12-26 Yeda Research And Development Co. Ltd use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
WO2013010537A1 (en) * 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
SG11201400513PA (en) 2011-09-08 2014-06-27 Yeda Res & Dev Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
AU2013284460A1 (en) 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
WO2014151230A2 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
CN106456712A (zh) 2014-04-25 2017-02-22 百时美施贵宝公司 Ctla4化合物用于在具有早期ra的受试者中实现无药物缓解的用途
JP2018512856A (ja) 2015-04-17 2018-05-24 アルパイン イミューン サイエンシズ インコーポレイテッド 調整可能な親和性を有する免疫調節タンパク質
PL3322424T3 (pl) 2015-07-16 2024-03-04 Yeda Research And Development Co., Ltd. Zastosowanie centralnych limfocytów t pamięci przeciwko stronie trzeciej
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
IL268126B2 (en) 2017-01-18 2024-02-01 Yeda Res & Dev Genetically engineered Veto cells and their uses in immunotherapy
CA3077509A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
AU2018351000B2 (en) 2017-10-18 2023-11-30 Alpine Immune Sciences, Inc. Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
WO2019175380A2 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019175381A1 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019175384A2 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
AU2020208909A1 (en) 2019-01-15 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
WO2023112992A1 (ja) * 2021-12-16 2023-06-22 レグセル株式会社 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US644792A (en) * 1899-09-14 1900-03-06 Stanhope Boal Heater.
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3424893A1 (de) 1984-07-06 1986-02-06 Agfa-Gevaert Ag, 5090 Leverkusen Photographisches silberhalogenidaufzeichnungsmaterial
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
JP3722375B2 (ja) 1991-06-27 2005-11-30 ブリストル−マイヤーズ スクイブ カンパニー Ｃｔｌａ４レセプター、それを含有する融合タンパク質およびそれらの使用
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5624823A (en) * 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
US5958403A (en) * 1992-02-28 1999-09-28 Beth Israel Hospital Association Methods and compounds for prevention of graft rejection
EP1488805A2 (en) 1992-04-07 2004-12-22 The Regents of the University of Michigan CD28 pathway immunoregulation
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
WO1994029436A1 (en) 1993-06-04 1994-12-22 The United States Of America Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
AU7107794A (en) 1993-06-10 1995-01-03 Regents Of The University Of Michigan, The Cd28 pathway immunosuppression
AU696235B2 (en) 1993-09-02 1998-09-03 Bristol-Myers Squibb Company Anti-GP39 antibodies and uses therefor
CN1142765A (zh) * 1993-12-01 1997-02-12 三共株式会社 以聚戊二烯基衍生物作为有效成分的炎症性细胞素产生抑制剂
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
WO1995033823A1 (en) 1994-06-03 1995-12-14 The United States Of America, Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
CA2191733A1 (en) 1994-06-07 1995-12-21 Daniel A. Vallera Methods for inhibiting antigen specific t cell responses
US5634055A (en) * 1994-09-27 1997-05-27 Bidplus, Inc. Method for selecting assignments
WO1996014865A1 (en) 1994-11-10 1996-05-23 Repligen Corporation Methods for inhibiting graft versus host disease in bone marrow transplantation
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5993800A (en) * 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5916560A (en) * 1996-03-20 1999-06-29 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith
JPH1067653A (ja) * 1996-06-17 1998-03-10 Eisai Co Ltd 関節疾患治療剤
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
KR19980066046A (ko) 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
AU748533B2 (en) 1997-06-11 2002-06-06 United States Of America As Represented By The Secretary Of The Navy, The Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses
EP0947524A1 (en) * 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
PT1066060E (pt) * 1998-04-03 2003-12-31 Osiris Therapeutics Inc Celulas estaminais mesenquimais como imunossupressores
CA2333726A1 (en) * 1998-06-05 1999-12-09 Supergen, Inc. Compositions comprising methotrexate and pentostatin for treating rheumatoid arthritis
JP2000086519A (ja) * 1998-09-17 2000-03-28 Mitsui Chemicals Inc 抗リウマチ薬効果増強剤
IL126681A0 (en) 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
WO2001090122A2 (en) 2000-05-23 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the ctla4 gene
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EE05458B1 (et) 2000-05-26 2011-08-15 Bristol-Myers Squibb Company CTL4 lahustuvad mutantsed molekulid ja nende kasutamine
AU2001275411B2 (en) * 2000-06-09 2005-04-28 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
BR0112104A (pt) * 2000-07-03 2004-07-20 Bristol Myers Squibb Co Processos para tratamento de doenças reumáticas usando uma molécula de ctla4 solúvel
JP2004535364A (ja) * 2001-01-26 2004-11-25 エモリー・ユニバーシティ 臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
ATE390931T1 (de) * 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen

Also Published As

Publication number Publication date
NO20026264D0 (no) 2002-12-27
TW200902546A (en) 2009-01-16
ES2310557T3 (es) 2009-01-16
ZA200210058B (en) 2005-02-23
DK1935427T3 (en) 2018-06-06
CY2008017I2 (el) 2016-08-31
EP1935427B1 (en) 2018-03-07
SK287940B6 (sk) 2012-05-03
LT1935427T (lt) 2018-05-10
PT1935427T (pt) 2018-05-16
JP2004517806A (ja) 2004-06-17
LT5063B (lt) 2003-11-25
LT2003002A (en) 2003-07-25
MY137552A (en) 2009-02-27
HRP20030071A2 (en) 2005-02-28
LV12993B (en) 2003-10-20
CN1477968A (zh) 2004-02-25
CA2630062C (en) 2014-10-14
RS50811B (sr) 2010-08-31
CA2413190C (en) 2009-04-07
AR066511A2 (es) 2009-08-26
AR035037A1 (es) 2004-04-14
IL153593A (en) 2009-09-01
HUS1000008I1 (hu) 2019-06-28
PE20020772A1 (es) 2002-09-06
CN1318086C (zh) 2007-05-30
IL153593A0 (en) 2003-07-06
CY1109786T1 (el) 2011-04-06
BG107362A (bg) 2003-09-30
PL212205B1 (pl) 2012-08-31
BG66024B1 (bg) 2010-11-30
PT1372696E (pt) 2008-10-24
BG110611A (bg) 2010-05-31
DK1372696T3 (da) 2008-11-03
ES2667203T3 (es) 2018-05-10
EP1372696A2 (en) 2004-01-02
AU7317401A (en) 2002-01-14
PL365942A1 (en) 2005-01-24
US7455835B2 (en) 2008-11-25
KR20080075564A (ko) 2008-08-18
WO2002002638A2 (en) 2002-01-10
NO20100579L (no) 2003-02-19
CY2008017I1 (el) 2009-11-04
TWI311564B (en) 2009-07-01
CZ303959B6 (cs) 2013-07-17
EP2281568A2 (en) 2011-02-09
BG66454B1 (bg) 2014-10-31
SI1372696T1 (sl) 2008-12-31
CY1120577T1 (el) 2019-07-10
TWI322153B (en) 2010-03-21
SK17742002A3 (sk) 2004-11-03
KR100864120B1 (ko) 2008-10-16
CZ20024261A3 (cs) 2004-08-18
KR20080025216A (ko) 2008-03-19
HRP20030071B1 (hr) 2014-01-03
EP2281568A3 (en) 2013-04-24
UY26815A1 (es) 2002-01-31
HUP0301727A3 (en) 2008-08-28
AU2001273174C1 (en) 2002-01-14
HUP0301727A2 (hu) 2003-09-29
KR20030017606A (ko) 2003-03-03
DE60135029D1 (de) 2008-09-04
AU2001273174B2 (en) 2006-05-18
PL207534B1 (pl) 2010-12-31
EP1935427A3 (en) 2011-05-25
BR0112104A (pt) 2004-07-20
KR100895552B1 (ko) 2009-04-29
EE200300004A (et) 2004-10-15
CA2630062A1 (en) 2002-01-10
YU101102A (sh) 2006-01-16
IS2834B (is) 2013-05-15
SI1935427T1 (en) 2018-05-31
MXPA02012603A (es) 2003-05-14
WO2002002638A3 (en) 2003-10-30
IS6667A (is) 2003-01-02
ATE401909T1 (de) 2008-08-15
EP3384924A1 (en) 2018-10-10
RU2287340C2 (ru) 2006-11-20
US20030083246A1 (en) 2003-05-01
HU226847B1 (en) 2009-12-28
HU227669B1 (en) 2011-11-28
CA2413190A1 (en) 2002-01-10
NO20100580L (no) 2003-02-19
EP1935427A2 (en) 2008-06-25
EP1372696B1 (en) 2008-07-23
EE05378B1 (et) 2011-02-15
NO20026264L (no) 2003-02-19
HK1058486A1 (en) 2004-05-21
TR201807700T4 (tr) 2018-06-21

Similar Documents

Publication Publication Date Title
DK1935427T3 (en) APPLICATIONS OF SOLUBLE, MUTANT CTLA4 MOLECULES
JP4328525B2 (ja) 可溶性ｃｔｌａ４突然変異体分子およびその用途
CA2447921C (en) Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
US8722632B2 (en) Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule
AU2001273174A1 (en) Methods for treating rheumatic diseases using a soluble CTLA4 molecule
DK1536234T3 (en) SOLUBLE MUTANT CTLA4 MOLECULES AND APPLICATIONS THEREOF

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20181106